Amended Claims

1. **(currently amended)** A composition for administering paclitaxel, **wherein:** ~~**comprising**~~

the composition is self-emulsifying;

the composition comprises:

(a) a paclitaxel or an analog thereof;

(b) a pharmaceutically acceptable surfactant;

(c) a pharmaceutically acceptable solvent; and

(d) a substituted cellulosic polymer; ~~**wherein**~~

the ~~**weight ratio of**~~ paclitaxel **and** ~~**to the**~~ surfactant ~~**(paclitaxel:surfactant) is**~~ **are present in a ratio of** from about 1:3 to about 1:20 **by weight; and**

the substituted cellulosic polymer and paclitaxel are present in a ratio of from about 50:1 to about 0.1:1 by weight.

Claim 2 (canceled).

3. **(original)** The composition of claim 1 which is for oral administration.

4. **(currently amended)** The composition of claim **1** **[[2]]** wherein said surfactant is selected from the group consisting of polyoxyl 40 hydrogenated castor oil, polyoxyl 35 hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, poloxamers, VE-TPGS 1000, polyoxyethylene alkyl ethers, Solutol HS-15, Tagat TO, Peglicol 6-oleate, polyoxyethylene sterates, and saturated polyglycolyzed glycerides.

5. **(original)** The composition of claim 4 wherein said surfactant is selected from the group consisting of polyoxyl 40 hydrogenated castor oil, polyoxyl 35 hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, poloxamers, and VE-TPGS 1000.

6. **(currently amended)** The composition of claim 5 wherein said surfactant is a polyoxyl 40 hydrogenated castor oil or polyoxyl 35 hydrogenated castor oil.

Claim 7 (canceled).

8. **(previously presented)** The composition of claim 1 wherein the weight ratio of paclitaxel to the surfactant (paclitaxel:surfactant) is from about 1:5 to about 1:10.

9. **(currently amended)** The composition of claim 1 [[2]] wherein said solvent is selected from the group consisting of polyethylene glycol, propylene glycol, ethanol, glycerol, triacetin, glycofurol, propylene carbonate, dimethyl acetamide; dimethyl isosorbide, N-methyl pyrrolidinone, and a mixture thereof.

10. **(original)** The composition of claim 9 wherein said solvent is selected from the group consisting of polyethylene glycol, propylene glycol, ethanol, and a mixture thereof.

11. **(original)** The composition of claim 10 wherein said solvent is a mixture of ethanol and a polyethylene glycol consisting of polyethylene glycol 400.

12. **(currently amended)** The composition of claim 1 [[2]] wherein the said substituted cellulosic polymer is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethylcellulose, methylcellulose, maltodextrin, and povidones.

13. **(original)** The composition of claim 12 wherein the said substituted cellulosic polymer is selected from the group consisting hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, and methylcellulose.

14. **(original)** The composition of claim 13 wherein said substituted cellulosic polymer is hydroxypropyl methylcellulose.

Claim 15 (canceled).

16. **(currently amended)** The composition of claim 1 **[[15]]** wherein said substituted cellulosic polymer and paclitaxel are present in a ratio of about 10:1 to about 0.1:1 by weight.

17. **(original)** The composition of claim 16 wherein said substituted cellulosic polymer and paclitaxel are present in a ratio of about 5:1 to about 0.5:1 by weight.

18. **(currently amended)** The composition of claim 1 **[[2]]** wherein said substituted cellulosic polymer is substantially water-soluble.

19. **(original)** The composition of claim 14 wherein the hydroxypropyl methylcellulose has about 15% to about 35% methoxyl substitution and about 4% to about 15% hydroxypropyl substitution.

20. **(original)** The composition of claim 19 wherein the hydroxypropyl methylcellulose has about 19% to about 24% methoxyl substitution and about 7% to about 12% hydroxypropyl substitution.

21. **(original)** The composition of claim 3 which is contained in a water-soluble capsule.

22. **(original)** The composition of claim 21 wherein the substituted cellulosic polymer is present in the capsule wall.

23. **(original)** The composition of claim 22 wherein the substituted cellulosic polymer constitutes from about 5% to 100% by weight of the capsule wall.

24. **(original)** The composition of claim 23 wherein the substituted cellulosic polymer constitutes from about 5% to 100% by weight of the capsule wall.

25. **(currently amended)** The composition of claim 1 **[[2]]** which further comprises a diglyceride.

26. **(original)** The composition of claim 25 wherein the diglyceride contains fatty acids of a carbon chain having 8 to 22 carbons with 0 to 3 double bonds.

27. **(original)** The composition of claim 26 wherein the diglyceride contains fatty acids of a carbon chain having 16 to 18 carbons with 1-2 double bonds.

28. **(original)** The composition of claim 25 wherein the diglyceride is selected from the group consisting of diolein, dilinoleate, and a mixture thereof.

29. **(original)** The composition of claim 25 which further comprises a monoglyceride.

30. **(original)** The composition of claim 29 wherein the monoglyceride contains fatty acids of a carbon chain having 8 to 22 carbons with 0 to 3 double bonds.

31. **(original)** The composition of claim 29 wherein the monoglycerides contains fatty acids of a carbon chain having 16 to 28 carbons with 1-2 double bonds.

32. **(original)** The composition of claim 29 wherein the monoglyceride is selected from the group consisting of monoolein, monolinoleate, and a mixture thereof.

33. **(original)** The composition of claim 29 wherein the ratio of diglyceride to monoglyceride (diglyceride:monoglyceride) by weight is from about 9:1 to about 6:4.

34. **(currently amended)** The composition of claim 1 **[[2]]** wherein the paclitaxel is present in an amount of up to about 100 mg/gm.

35. **(original)** The composition of claim 34 wherein the paclitaxel is present in an amount of from about 10 to about 80 mg/gm.

36. **(original)** The composition of claim 35 wherein the paclitaxel is present in an amount of from about 30 to 70 mg/gm.

37. **(original)** The composition of claim 36 wherein the paclitaxel is present in an amount of from about 40 mg/gm to about 65 mg/gm.

38. **(original)** The composition of claim 1 wherein said surfactant is present in an amount from about 100 to about 700 mg/g.

39. **(currently amended)** The composition of claim 1 [[2]] wherein said solvent is present in an amount from about 100 to about 700 mg/g.

40. **(original)** The composition of claim 3 further comprising a P-glycoprotein inhibitor.

41. **(original)** The composition of claim 40 wherein said P-glycoprotein inhibitor is selected from the group consisting of alginates, xanthan, gellan gum, CRK-1605, cyclosporin A, verapamil, tamoxifen, quinidine, valspodar, SDZ PSC 833, GF120918 (GG918, GW0918), ketocomazole, Psoralens, sucroster-15, R101933, OC144-093, Erythromycin, azithromycin, RS-33295-198, MS-209, XR9576, and phenothiazine.

42. **(original)** The composition of claim 41 wherein said P-glycoprotein inhibitor is cyclosporin A.

43. **(original)** The composition of claim 42 wherein said cyclosporin A in the composition is in an amount of from about 0.1 to about 20 mg/kg patient body weight.

44. **(original)** The composition of claim 1 wherein the surfactant is selected from the group consisting of polyoxyl 40 hydrogenated castor oil, polyoxyl 35 hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, poloxamers, vitamin E-TPGS 1000, polyoxyethylene alkyl ethers, Solutol HS-15, Tagat TO, Peglicol 6-oleate, polyoxyethylene sterates, and saturated polyglycolyzed glycerides; and wherein the substituted cellulosic polymer is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethylcellulose, methylcellulose, maltodextrin, and povidones.

45. **(original)** The composition of claim 44 wherein the surfactant is selected from the group consisting of polyoxyl 40 hydrogenated castor oil and a polyoxyl 35 hydrogenated castor oil; wherein the solvent is selected from the group consisting of polyethylene glycol, propylene glycol, ethanol, and a mixture thereof; and wherein the substituted cellulosic polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, and methylcellulose.

46. **(original)** The composition of claim 45 wherein the surfactant is a polyoxyl 35 hydrogenated castor oil; wherein the solvent is a mixture of polyethylene glycol ethanol; and wherein the substituted cellulosic polymer is hydroxypropyl methylcellulose.

47. **(original)** The composition of claim 45 further comprising a diglyceride.

48. **(original)** The composition of claim 47 wherein the diglyceride is glyceryl dioleate.

49. **(withdrawn and currently amended)** A method of treating a patient suffering from cancer and in need of treatment, **wherein:**

the method comprises administering ~~**comprising administration to said patient**~~ **a self-emulsifying** composition **to the patient;** ~~**comprising**~~

the composition comprises:

(a) a chemotherapeutically effective amount of paclitaxel,

(b) a pharmaceutically acceptable surfactant,

(c) a pharmaceutically acceptable solvent, and

(d) **a** [[s]] substituted cellulosic polymer**;**

the paclitaxel and surfactant are present in a ratio of from about 1:3 to about 1:20 by weight; and

the substituted cellulosic polymer and paclitaxel are present in a ratio of from about 50:1 to about 0.1:1 by weight.

50. **(withdrawn)** The method of claim 49 wherein the amount of said paclitaxel in the composition is from about 10 to about 80 mg/g.

51. **(withdrawn)** The method of claim 50 wherein the amount of said paclitaxel in the composition is from about 30 to about 70 mg/g.

52. **(withdrawn)** The method of claim 51 wherein the amount of said paclitaxel in the composition is from about 40 to about 65 mg/g.

53. **(withdrawn)** The method of claim 49 wherein said composition further comprises a diglyceride.

54. **(withdrawn)** The method of claim 53 wherein said composition further comprises a monoglyceride.

55. **(withdrawn)** The method of claim 54 wherein the ratio of the diglyceride to monoglyceride, by weight, in the composition is from 9:1 to about 6:4.

56. **(withdrawn)** The method of claim 53 wherein the composition is administered orally.

57. **(withdrawn)** The method of claim 56 wherein the composition further comprises a P-glycoprotein inhibitor.

58. **(withdrawn)** The method of claim 58 wherein said P-glycoprotein inhibitor is selected from the group consisting of cyclosporine A, verapamil, tamoxifen, quinidine, phenothiazine, and mixtures thereof, or related P-glycoprotein inhibitors.

59. **(withdrawn)** The method of claim 57 wherein the amount of said P-glycoprotein inhibitor in the composition is from about 0.1 to about 20 mg/kg patient body weight.

60. **(original)** The composition of claim 14 wherein the hydroxypropyl methylcellulose has a viscosity range of about 1 to 1 about 100,000 cps.

61. **(original)** The composition of claim 60 wherein the hydroxypropyl methylcellulose has a viscosity range of about 1 to about 4,000 cps.

62. **(original)** The composition of claim 14 wherein the hydroxypropyl methylcellulose is type 2208 or 2910.

63. **(previously presented)** The composition of claim 21 wherein the substituted cellulosic polymer is present in the fill liquid composition of the water-soluble capsule.

64. **(original)** The composition of claim 1 which generates a supersaturated state upon dilution with water.